The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
10.1016/j.jalz.2014.07.003 · doi-reference
Practical use of DAT SPECT in diagnosing dementia with Lewy bodies: a US perspective
10.3389/fneur.2024.1395413 · doi-reference
EFNS guidelines for the diagnosis and management of Alzheimer’s disease
10.1111/j.1468-1331.2010.03040.x · doi-reference
Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline
10.1111/j.1468-1331.2006.01605.x · doi-reference
Optimizing use of neuroimaging tools in evaluation of Alzheimer’s disease and related dementias
10.3233/jad-200487 · doi-reference
ARIA monitoring in clinical practice: updated considerations for anti-amyloid immunotherapy
10.3174/ajnr.a8469 · doi-reference
Lecanemab: appropriate use recommendations
10.14283/jpad.2023.30 · doi-reference
Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice
10.3174/ajnr.a7586 · doi-reference
A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer’s disease
10.1186/s13195-022-00985-x · doi-reference
Multimodal deep learning for Alzheimer’s disease dementia assessment
10.1038/s41467-022-31037-5 · doi-reference
Antemortem differential diagnosis of dementia pathology using structural MRI: differential–STAND
10.1016/j.neuroimage.2010.12.073 · doi-reference
Direct comparison of the tau PET tracers [18F]flortaucipir and [18F]MK-6240 in human subjects
10.2967/jnumed.120.254961 · doi-reference
Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
10.1038/s43587-022-00204-0 · doi-reference
Tau PET positivity varies with age, amyloid status, APOE genotype, and sex across the Alzheimer’s disease spectrum
10.1038/s41593-025-02000-6 · doi-reference
Amyloid- and tau-PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
10.1038/s41591-022-02049-x · doi-reference
Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease
10.1001/jamaneurol.2021.1858 · doi-reference
Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease
10.1093/brain/awx243 · doi-reference
An expanded role for neuroimaging in the evaluation of memory impairment
10.3174/ajnr.a3644 · doi-reference
Three dimensions of the amyloid hypothesis: time, space and “wingmen.”
10.1038/nn.4018 · doi-reference
Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial
10.1001/jama.2023.13239 · doi-reference
Lecanemab in early Alzheimer’s disease
10.1056/nejmoa2212948 · doi-reference
FDG PET for monitoring immunotherapy in Alzheimer’s disease
10.3390/diagnostics13132254 · doi-reference
Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease
10.1093/brain/awl178 · doi-reference
Relationship between atrophy and β-amyloid deposition in Alzheimer disease
10.1002/ana.21955 · doi-reference
Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests
10.1038/s41591-024-02869-z · doi-reference
Blood biomarkers to detect Alzheimer disease in primary care and secondary care
10.1001/jama.2024.13855 · doi-reference
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
10.1038/s43587-023-00471-5 · doi-reference
Updated appropriate use criteria for amyloid and tau PET
10.1002/alz.14338 · doi-reference
New IDEAS study: amyloid PET in a racially and ethnically diverse population
10.1002/alz.70504 · doi-reference
Amyloid PET and subsequent health care use among Medicare beneficiaries with mild cognitive impairment or dementia (IDEAS study, aim 2)
10.1001/jamaneurol.2023.3490 · doi-reference
Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia
10.1001/jama.2019.2000 · doi-reference
Cerebrospinal fluid Aβ42 levels: when physiological become pathological state
10.1111/cns.12476 · doi-reference
Amyloid-β deposition and regional grey matter atrophy rates in dementia with lewy bodies
10.1093/brain/aww193 · doi-reference
Clinical amyloid imaging
10.1053/j.semnuclmed.2016.09.005 · doi-reference
Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the IDEAS study
10.1001/jamaneurol.2022.3157 · doi-reference
Brain imaging in Alzheimer disease
10.1101/cshperspect.a006213 · doi-reference
